藥明巨諾(02126.HK)瑞基奧侖賽注射液治療淋巴瘤患最佳客觀緩解率為77.6%
藥明巨諾-B(02126.HK)公布,倍諾達(瑞基奧侖賽注射液)治療中國難治/復發性彌漫大B淋巴瘤患者的多中心II期RELIANCE臨床研究顯示,在58例可評估有效性患者中,最佳客觀緩解率(ORR)為77.6%,最佳完全緩解率(CRR)為53.5%,2年總生存率(OS)為69%;
在倍諾達二線治療中國原發耐藥性彌漫大B細胞淋巴瘤患者的I期開放、單臂、多中心研究的初步有效性和安全性結果中,顯示瑞基奧侖賽具有良好的安全性,對於有效性可評估的患者,ORR為75.0%,CRR為33.3%,3個月的ORR、CRR分別為41.7%、33.3%。中位緩解持續時間、中位OS均未達到。
在倍諾達治療難治和復發性B細胞非霍奇金淋巴瘤患者的1期研究的兩年生存隨訪資料顯示,基於20例患者的有效性分析集,ORR為85%,CRR為70%。1年和2年的無進展生存率均為55.0%,總生存率率均為68.6%。中位PFS、OS均未達到。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.